Trump Tariff Hits Pharma Shares; Sensex Falls 733 Points to 80,426 on Fifth Consecutive Day

Business News: The Indian stock market on Friday recorded a huge decline after US President Donald Trump's announcement of imposing 100% tariffs on the import of branded and patent drugs from 1 October. The BSE Sensex fell over 800 points to 80,400 levels during trading. Finally, the Sensex closed at 80,426.46 points, declining 733.22 points, or 0.90%. At the same time, the Nifty 50 also fell 238.35 points i.e. 0.96% to close at 24,652.50 points.

The most impact on the pharma sector

After Trump's decision, the most pressure was seen in the shares of Indian pharma companies. The Nifty Pharma fell 590 points or 2.7% to the lowest level of the day of 21,390.25. Of the 20 shares of this sector, 17 were in red mark. Large shares like Laus Labs, Biocon, Zayadas LifeSyins and Natco Pharma have fallen by up to 7%. Investors considered it a negative sign.

Continuous decline throughout the week

The stock market was under pressure this week in the sixth consecutive season. The Sensex has fallen more than 1,850 points from Monday to Friday. The Nifty 50 has also broken about 600 points this week. According to experts, besides the US tariff decision, the selling of foreign institutional investors was also the main cause of pressure in the market.

Pressure in global markets

On Friday, Asian markets also came under selling pressure. Japan's Nikkei was 0.9%, Hong Kong's Hang Seng 1.4% and China's Shanghai Composite was 0.7% below. Heavy selling by foreign investors also affected the domestic market. On Thursday, FIIs sold shares worth Rs 4,995.42 crore. So far in September, they have sold domestic shares worth Rs 13,450 crore, and in 2025 so far, they have sold shares worth Rs 144,085 crore.

Opinion of experts

Financial analysts say that Trump's tariff decision has affected global sales and Indian pharma companies. This has increased the fear among foreign investors, leading to continued selling in the market.